Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides combination therapies that include CV-8972 and CV-8814. The combination therapies improve cardiac efficiency and thus are useful for treating cardiovascular conditions in a subject. The invention also provides methods of treating conditions using both CV-8972 and CV-8814 and pharmaceutical compositions that contain both CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism.

Abstract: The invention provides methods for altering cardiac remodeling in a subject by providing a compound that shifts cellular metabolism from fatty acid oxidation to glucose oxidation.

Abstract: The invention provides methods for treating or preventing fibrosis in a subject by providing a compound that shifts cellular metabolism from fatty acid oxidation to glucose oxidation.

Abstract: The invention provides methods of treatment of heart failure with hibernating myocardium using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides compositions and methods for treating a subject having cancer.

Abstract: The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modified form of trimetazidine and it metabolic products in the body. The invention also provides methods of treating conditions, including angina and heart failure, using such compositions.

Abstract: The invention generally relates to non-oral formulations of TCA cycle intermediates and methods of using such formulations for treating metabolic disorders. In certain embodiments, the invention provides therapeutic compositions containing succinate formulated for non-oral administration and methods of using such compositions to treat metabolic disorders. The invention also provides combination therapies that include compositions containing succinate formulated for non-oral administration and compositions containing citrate (optionally formulated for oral administration) and methods of using such combination therapies to treat metabolic disorders.

Abstract: A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.

Abstract: A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.

Abstract: A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.

Abstract: A pharmaceutical composition comprising Compound (1), characterised in that the composition comprises 2 to 12 mg of Compound (1) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.